Recent Quotes (30 days)

You have no recent quotes
chg | %

Venturi Ventures Inc  

(Public, CVE:URO)   Watch this stock  
Find more results for URO
- Close
CVE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.01 - 0.12
Open     -
Vol / Avg. 0.00/107,574.00
Mkt cap 1.38M
P/E 0.00
Div/yield     -
EPS 0.15
Shares     -
Beta 0.51
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -585.18% -279.26%
Operating margin -950.40% -689.26%
EBITD margin - -689.26%
Return on average assets -11.92% -6.82%
Return on average equity -12.82% -8.07%
Employees 16 -
CDP Score - -


Suite 410, 221 West Esplanade
+1-604-6947770 (Phone)
+1-604-6947771 (Fax)


Venturi Ventures Inc, formerly Urodynamix Technologies ltd is engaged in the development of non invasive medical technology and diagnostic devices based on near infrared spectroscopy and the development and marketing of its Advanced Verification of Integration Dose technology. The Company had developed and commercialized a medical device to aid in the diagnosis and treatment of urinary incontinence and lower urinary tract symptoms and had developed a portfolio of technology to aid in the diagnosis of intra-abdominal pressure that cause abdominal compartment syndrome and improve the efficacy of the minimally invasive treatment of benign prostatic hypertrophy.

Officers and directors

James L. Heppell Chairman of the Board, Chief Executive Officer
Age: 58
Sean P. Hodgins Chief Financial Officer, Secretary
Kirk Exner Director
David John Raffa Director
Ron G. Palfery Independent Director